All News

Found 757,483 articles

• Microbion Corporation CEO to Present at the 2023 BIO CEO & Investor Conference

  2/3/2023

  Microbion Corporation, a clinical stage pharmaceutical company, announced that Karim Lalji, CEO of Microbion Pharma Corp., will be presenting at the 2023 BIO CEO & Investor Conference in New York, NY.

• Dexlevo’s GOURI Symposium and Brand Event at IMCAS 2023

  2/3/2023

  Dexlevo, a company specializing in aesthetic medical devices, successfully held a symposium dedicated to its exclusive product, ‘GOURI’, at the IMCAS World Congress 2023 in Paris.

• Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

  2/3/2023

  Orexo AB, announces the submission of a New Drug Application to the US Food and Drug Administration for its lead pharmaceutical pipeline asset, OX124, a nasal rescue medication for opioid overdose.

• Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone

  2/3/2023

  Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone

• Cellectis Announces Pricing of Follow-On Offering - February 03, 2023

  2/3/2023

  Cellectis S.A. announces the pricing of its previously announced underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares.

• Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors

  2/3/2023

  Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its ARM vaccine manufacturing

• Mindset Pharma Announces Grant of Options

  2/3/2023

  Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") announces that it has granted an aggregate of 6,065,000 options to purchase common shares of the Company

• Cigna Reports Strong Fourth Quarter and Full Year 2022 Results, Establishes 2023 Guidance and Increases Dividend

  2/3/2023

  Global health services company Cigna Corporation reported strong 2022 results reflecting growth in both Evernorth and Cigna Healthcare.

• Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital

  2/3/2023

  Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has entered into a common stock purchase agreement for a committed equity financing (the "Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC"), a long-standing investor in the Company.

• KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

  2/3/2023

  KalVista Pharmaceuticals, Inc. today announced it will be presenting at the SVB Securities Global Biopharma Conference (virtual) on Thursday, February 16, 2023 at 8:40 a.m. ET.

• BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

  2/3/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held in San Antonio, Texas, from February 24-27, 2023.

• Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference - February 3, 2023

  2/3/2023

  Tonix Pharmaceuticals Holding Corp. today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate virtually in the BIO CEO & Investor Conference, which is being held February 6-9, 2023.

• Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023

  2/3/2023

  Celldex Therapeutics, Inc. announced today that data from the Company’s Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023 being held February 24-27 in San Antonio, Texas.

• Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

  2/3/2023

  Monte Rosa Therapeutics, Inc. today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events.

• Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference

  2/3/2023

  Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023.

• Tvardi Therapeutics to Present at the Guggenheim Securities Oncology Conference

  2/3/2023

  Tvardi Therapeutics, Inc. announced that the management team will present at the Guggenheim Securities Oncology Conference on Wednesday, February 8, 2023, in New York City as well as host one-on-one meetings throughout the day.

• Announcing the Launch of The Association of Diversity in Clinical Trials

  2/3/2023

  The Association of Diversity in Clinical Trials (AOD) is being launched and introduced at upcoming industry conferences SCOPE and the Health Equity in Clinical Trials Congress this month.

• Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer

  2/3/2023

  Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.

• SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions

  2/3/2023

  SpyGlass Pharma, a privately held ophthalmic therapeutics company, released 6-month data from a First-in-Human glaucoma treatment trial showing that its breakthrough drug delivery platform continues to demonstrate significant intraocular pressure (IOP) lowering in patients with glaucoma or ocular hypertension.

• Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting

  2/3/2023

  Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of AYVAKIT® (avapritinib) in indolent systemic mastocytosis (SM) at the 2023 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, February 24 to 27 in San Antonio.